Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.51 |
| ▸ | PPARD | Q03181 | 6/20 | 0.51 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2822704 | 0.92 | PPARA (0.43) | PPARAPPARDPPARGTBXAS1KMT2A | |
| SCHEMBL2821806 | 0.90 | PPARA (0.46) | PPARAPPARDPPARGTBXAS1 | |
| SCHEMBL2820111 | 0.89 | PPARA (0.43) | PPARAPPARDPPARGTBXAS1 | |
| SCHEMBL2821367 | 0.87 | PPARA (0.44) | PPARAPPARDPPARGTBXAS1 | |
| SCHEMBL2820164 | 0.87 | PPARA (0.44) | PPARAPPARDPPARGTBXAS1 | |
| SCHEMBL2819419 | 0.84 | PPARA (0.72) | PPARAPPARDPPARG | |
| SCHEMBL2819490 | 0.83 | PPARA (0.45) | PPARAPPARDPPARGTBXAS1NPC1 | |
| SCHEMBL2819934 | 0.82 | PPARA (0.43) | PPARAPPARDPPARGTBXAS1NPC1 | |
| SCHEMBL2820480 | 0.82 | PPARG (0.42) | PPARAPPARDPPARGTBXAS1KMT2A | |
| SCHEMBL2819367 | 0.81 | PPARA (0.55) | PPARAPPARDPPARGTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | claimed |
| WO-2010071813-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α | ARYX THERAPEUTICS, INC. (US) | 2010-06-24 | — | — | WO | claimed |
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184815-A1 | AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-ALPHA | PPARA, PPARD, PPARG | PPARA 1/4885PPARD 2/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.